Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study

The six-month findings come from a 30-patient pilot without a randomized or sham-controlled comparator.

Rhea-AI Summary

Creative Medical Technology Holdings (CELZ) reported a 93% study-defined response rate in a pilot study of investigational Ultrasome for knee osteoarthritis. The study followed 30 patients with bilateral knee osteoarthritis for six months; 28 met response criteria. The group-average pain score fell approximately 65% from baseline, rather than 65% of patients reporting improvement.

Average WOMAC scores, measuring pain, stiffness and physical limitations, decreased 52%, while average knee-related quality-of-life scores rose approximately 35 points. No serious adverse events were reported during follow-up. The open-label, single-arm pilot had no randomized or sham-controlled comparator. The company anticipates including full scientific findings in a manuscript planned for peer-reviewed publication.

Positive

• Minor point28 of 30 participants (93%) met study-defined criteria for clinical improvement.
• Minor pointGroup-average pain score declined approximately 65% from baseline to six months.
• Minor pointAverage WOMAC score decreased 52% over six months, reflecting improved osteoarthritis symptoms and physical limitations.
• Minor pointAverage knee-related quality-of-life score increased approximately 35 points.
• Minor pointNo serious adverse events were reported during six months of follow-up.

2 minor points

• Minor pointLaboratory studies showed reductions in biological markers associated with cartilage degradation and inflammatory signaling.
• Minor point. Forward-looking: it has not happened yet and may not happen.Full scientific findings are anticipated for inclusion in a manuscript planned for peer-reviewed publication.

Negative

• Minor pointOpen-label, single-arm pilot involved 30 patients without a randomized or sham-controlled comparator.

News Explained

CELZ also reports laboratory reductions in markers associated with cartilage degradation and inflammatory signaling, plus product-characterization and potency findings supporting further evaluation of manufacturing controls and consistency; detailed potency analyses are planned for a peer-reviewed manuscript.

Key Figures

Study response: 28 of 30 participants (93%) Average pain score reduction: Approximately 65% Average WOMAC score reduction: 52% +2 more

Study response

28 of 30 participants (93%)

Met study-defined response criteria

Average pain score reduction

Approximately 65%

From baseline to six months

Average WOMAC score reduction

52%

Over six months

Knee-related quality-of-life score increase

Approximately 35 points

Group average

Serious adverse events

None reported

Six months of follow-up

Historical Context

1 past event · Latest: Jul 01

1 event

1. Jul 01

   mid-year update

   24h Move

   -12.4%

   Previously reported a 93% responder rate in the Ultrasome osteoarthritis pilot.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

womac, open-label, single-arm, extracellular-vesicle-rich secretome

4 terms

womac medical

"52% reduction in average WOMAC score"

A WOMAC is a standardized questionnaire patients complete to rate joint pain, stiffness, and ability to perform everyday activities, most often used for osteoarthritis. Think of it as a customer-satisfaction score for joints that translates how people actually feel and function into numbers. Investors watch WOMAC results because they are commonly used to show whether a treatment meaningfully helps patients, influencing regulatory approval, prescribing decisions and market value.

open-label medical

"The 30-patient study was an open-label"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

single-arm medical

"open-label, single-arm pilot without a randomized"

A single-arm study is a clinical trial that gives all participants the same treatment and does not include a separate comparison group or placebo. Think of it like testing a new recipe by serving it to diners without offering a control dish — you can see how people respond, but you can’t directly compare results to another option. For investors, single-arm trials can speed development and reduce cost but leave more uncertainty about how a treatment stacks up against existing therapies and how regulators will view the evidence.

extracellular-vesicle-rich secretome technical

"using extracellular-vesicle-rich secretome material"

The collection of molecules and particles that a cell or group of cells releases into their surrounding fluid, where extracellular vesicles (small membrane-bound particles such as exosomes and microvesicles) make up a large portion of the material. It typically refers to cell culture-conditioned media or bodily-fluid-derived preparations that have been processed or concentrated so that extracellular vesicles are abundant relative to soluble proteins and free nucleic acids. Composition and biological activity depend on the cell source and processing method, and the phrase denotes a preparation enriched for—but not composed exclusively of—extracellular vesicles.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

International Scientific Presentation Underscores Encouraging Clinical Outcomes and Additional Biological Potency Findings Supporting Cell-Free Regenerative Platform

PHOENIX, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine technologies, today highlighted additional clinical and laboratory findings for Ultrasome™, its investigational cell-free regenerative medicine platform, following a presentation at the Annual Meeting of Experts in Cell and Gene Therapy held October 10, 2026, in Lima, Peru.

The study evaluated 30 patients with bilateral knee osteoarthritis over six months and found that 28 of 30 participants (93%) met study-defined response criteria. Importantly, the group’s average reported pain score declined by approximately 65% from baseline to six months. The 65% figure refers to the reduction in the group-average pain score - not the percentage of patients reporting improvement.

Clinical Results: 93% Response and Meaningful Average Symptom Improvement

• 93% patient response: 28 of 30 participants met the study-defined criteria for clinical improvement.
• 65% reduction in average pain score at six months post intervention.
• 52% reduction in average WOMAC score: Mean scores reflecting osteoarthritis-related pain, stiffness and physical limitations improved over six months.
• Improved quality of life: The group’s average knee-related quality-of-life score increased by approximately 35 points.
• Preliminary safety: No serious adverse events were reported during six months of follow-up.

Additional Scientific Findings Support Ultrasome™ Platform Development

Complementing the clinical observations, laboratory studies demonstrated significant reductions in biological markers associated with cartilage degradation and inflammatory signaling. Product characterization and functional potency testing also provided encouraging findings supporting further evaluation of manufacturing quality controls and product consistency.

The Company anticipates that the full scientific findings, including detailed potency analyses, statistical evaluations, tables and figures, will be included in a manuscript planned for peer-reviewed publication.

A Scalable Cell-Free Regenerative Medicine Opportunity

Ultrasome™ builds upon Creative Medical’s regenerative medicine technology platform associated with CELZ-201 (Olastrocel), using extracellular-vesicle-rich secretome material in an investigational cell-free therapeutic approach. The Company believes this strategy may offer potential future advantages in manufacturing, distribution and development across osteoarthritis and other degenerative conditions.

“These findings represent an encouraging milestone for Ultrasome,” said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. “With 93% of patients meeting study-defined response criteria and an approximately 65% reduction in the group’s average pain score, we believe the results strengthen the rationale for further development. The additional potency findings reinforce our focus on a scalable, biologically active regenerative medicine platform with significant long-term opportunity.”

The 30-patient study was an open-label, single-arm pilot without a randomized or sham-controlled comparator.

About Ultrasome™

Ultrasome™ is Creative Medical’s investigational cell-free regenerative medicine platform utilizing extracellular-vesicle-rich secretome material. Ultrasome™ is not FDA-approved for knee osteoarthritis or other indications.

About Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company developing regenerative medicine technologies, including cell-based and cell-free approaches, targeting significant unmet medical needs. For more information, visit www.creativemedicaltechnology.com.

Forward-Looking Statements

This press release contains forward-looking statements concerning Ultrasome™, future research, clinical development, regulatory pathways, manufacturing, potential applications and commercialization opportunities. Actual results may differ materially due to risks including the possible failure to reproduce preliminary findings in controlled studies, regulatory decisions, manufacturing challenges, financing needs and other factors described in the Company’s SEC filings. The Company undertakes no obligation to update these statements except as required by law.

Investor & Media Contacts

Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
www.creativemedicaltechnology.com

Investor Relations / The Equity Group Inc.
Devin Sullivan
devin.sullivan@theequitygroup.com

Conor Rodriguez
conor.rodriguez@theequitygroup.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Creative Medical's CELZ Ultrasome knee osteoarthritis study show?

28 of 30 participants (93%) met study-defined response criteria over six months. The group-average pain score declined approximately 65% from baseline. That reduction describes the average pain score, not the percentage of patients reporting improvement.

Was Creative Medical's Ultrasome knee osteoarthritis study randomized?

The Ultrasome study was an open-label, single-arm pilot without a randomized or sham-controlled comparator. It evaluated 30 patients with bilateral knee osteoarthritis over six months.